Equities Analysts Set Expectations for AXSM FY2028 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Leerink Partnrs decreased their FY2028 earnings estimates for Axsome Therapeutics in a report released on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $9.70 for the year, down from their previous forecast of $9.90. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2029 earnings at $16.85 EPS.

A number of other equities research analysts have also recently issued reports on AXSM. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday. HC Wainwright upped their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday. Royal Bank of Canada upped their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday. Needham & Company LLC upped their price objective on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Bank of America upped their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and an average price target of $155.47.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $129.15 on Thursday. The business’s fifty day moving average price is $100.34 and its 200 day moving average price is $94.46. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $134.18. The stock has a market capitalization of $6.26 billion, a PE ratio of -21.56 and a beta of 1.05. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 195.76%. The business had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of AXSM. Creative Planning increased its holdings in Axsome Therapeutics by 29.8% in the 3rd quarter. Creative Planning now owns 10,854 shares of the company’s stock worth $975,000 after purchasing an additional 2,489 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at about $568,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Axsome Therapeutics by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company’s stock valued at $1,780,000 after buying an additional 754 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Axsome Therapeutics by 65.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,232 shares of the company’s stock valued at $830,000 after buying an additional 3,652 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.